Anti-Mouse CD18 (Clone C71/16) – Purified in vivo GOLD™ Functional Grade

Clone C71/16 is a rat monoclonal antibody that binds specifically to mouse CD18 (integrin β2, the common β subunit of LFA-1 and Mac-1), and its most common in vivo applications in mice are in studies of immune cell adhesion, trafficking, and function, particularly through functional blocking and detection of CD18 on leukocytes.

Core in vivo applications include:

• Functional blocking of CD18 activity: C71/16 is used to functionally inhibit CD18-mediated interactions (such as leukocyte adhesion and migration) in vivo in mouse models of inflammation, autoimmune disease, infection, and organ transplantation. By blocking CD18, researchers assess its critical role in leukocyte recruitment and host defense.

• Flow cytometric detection of CD18 expression on murine leukocytes: The antibody is widely used in flow cytometry to label and quantify CD18 surface expression on different immune cell populations in blood and tissues. This is vital for studies investigating leukocyte activation, trafficking, and immunophenotyping under various experimental conditions.

• Assessment of neutrophil and monocyte function: As CD18 is integral to neutrophil and monocyte adhesion and transmigration, C71/16 can be applied in vivo to measure changes in cell recruitment to sites of inflammation after antibody treatment or genetic manipulation.

• Immunohistochemistry (IHC): Although less common in vivo than flow cytometry or direct functional studies, C71/16 can be used to stain tissue sections and visualize CD18-expressing cells in the context of tissue inflammation or pathology.

Supporting context:

• Blocking studies: C71/16 functional grade antibody preparations are designed for in vivo use and are tested to ensure low endotoxin levels and pathogen-free status to avoid confounding experimental outcomes.

• Role of CD18: CD18 is the β chain shared by several β2 integrins, essential for leukocyte adhesion and transmigration. Blocking or depleting CD18 impairs immune cell recruitment to inflamed tissues, which is used to model immunodeficiency or leukocyte adhesion deficiency in mice.

Summary table:

If you require specific in vivo disease models or protocols where C71/16 is employed, provide the context (e.g., autoimmune, infectious, or transplant models), as application details can vary by field.

The C71/16 monoclonal antibody specifically targets mouse CD18, which is a common β2 integrin subunit crucial in forming various integrin heterodimers like CD11a/CD18 (αLβ2 integrin) . While the search results do not specifically mention other antibodies or proteins commonly used with C71/16, researchers often employ a combination of antibodies to study complex immunological processes. Commonly used antibodies in immunological research that might be used in conjunction with C71/16 include:

• CD11a/CD11b/CD11c Antibodies: These are often used alongside CD18 to study integrin functions and cellular interactions.
• CD3/CD4/CD8 Antibodies: These are used to identify T-cell subsets and their interactions with other immune cells.
• CD19/CD20 Antibodies: These target B cells and are used in studies involving B-cell development and function.
• CD45 Antibodies: Useful for identifying and isolating leukocytes.

In terms of proteins, molecules involved in cell adhesion and signaling, such as ICAM-1 and VCAM-1, are studied in conjunction with CD18 as they are ligands for some of the integrin complexes formed with CD18.

These combinations allow researchers to explore the complex interactions and functions within the immune system effectively.

Key findings from scientific literature citing clone C71/16 predominantly concern its use as a monoclonal antibody for rat CD18 detection, facilitating research on leukocyte integrins, cell adhesion, and immune responses.

• Clone C71/16 is widely cited as an antibody that specifically targets rat CD18, a subunit of β2 integrins (such as LFA-1, Mac-1), which play essential roles in leukocyte adhesion and migration.
• Its validated specificity allows for reliable identification and measurement of CD18 expression on rat leukocytes using flow cytometry and other immunological assays.
• Research employing clone C71/16 has contributed to understanding the regulation of neutrophil activation, inflammation, and immune cell trafficking, enabling studies that distinguish functional states of immune cells based on CD18 surface expression and dynamics.

Additional context:

• Studies using clone C71/16 have helped characterize the shedding, activation, and deactivation of integrin complexes in rat models, including investigations into synovial inflammation and arthritis.
• This clone is frequently referenced in studies employing BD Biosciences rat anti-CD18 reagents for experimental protocols, ensuring reproducible results due to its established track record in immunology research.

In summary, clone C71/16 is recognized in scientific literature as a critical reagent for functional and phenotypic analysis of rat β2 integrins, thereby enabling discoveries in leukocyte biology, inflammation, and immune regulation.

No dosing regimens for the antibody clone C71/16 are reported in the provided search results. The sources include detailed dosing protocols for other antibody clones (such as anti-PD-1 or anti-CTLA-4), as well as general discussions of antibody dosages in mouse models, but there is no mention of C71/16 specifically.

Essential context:

• C71/16 is not cited in any of the key dosing guides or mouse model protocols in the results.
• Dosing for comparable antibodies in mouse models typically ranges between 100–500 µg per mouse per dose, given intraperitoneally and repeated every 2–4 days, but this is not specific to C71/16.
• Other antibodies directed against related targets (for example, anti-midkine or anti-PD-1) show that dosing generally depends on mouse weight, antibody pharmacokinetics, and the disease model being studied.

Recommendations if you are optimizing C71/16 dosing:

• Start with the common antibody dose range used for preclinical studies (e.g., 10 mg/kg or 200–500 µg/mouse) unless pilot or prior data suggests otherwise.
• Adjust the regimen according to the target antigen, immunogenicity, and specific disease model.

If you need C71/16-specific data:

• Review primary literature or product datasheets for studies that deployed clone C71/16 in vivo.
• Consider contacting the original developer or manufacturer if clone-specific in vivo data is not published.

In summary, without specific published data for C71/16, only general guidance based on similar antibody regimens in mouse models can be offered, and C71/16-specific studies should be consulted directly for precise regimens.